Facial expression

XRSPACE Partners With Meta and TAICCA Enabling World's First Thousand-Year Matsu Religion Into the Metaverse

Retrieved on: 
Friday, September 23, 2022
People, Metaverse, Tablet, Culture, Human, 3D, Facial expression, Chaotian Temple, Museum, Creativity, Partnership, KK, IPS, Technology, Meta, Montreal, Work, Ecosystem, Motion, Public policy, XR, AI, Education, View, Entertainment, Tourism

TAIPEI, Sept. 23, 2022 /PRNewswire/ -- XRSPACE announces its partnership with Meta and Taiwan Creative Content Agency (TAICCA) in recreating the famous Matsu religion hub - Beigang Chaotian Temple in the metaverse, establishing the world's first Matsu metaverse. Followers around the world will be able to engage in certified Matsu rituals such as Guangming Lights, Moon Block Divination, Fortune-Changing Bells, and Fortune Poem Readings wherever they are. In addition to rituals, the excitement Matsu metaverse also brings is the plan to host many cultural expos and entertainment events. The full experience will launch on October 4th, starting with artists and creators to participate in the "People's Matsu Art Contest," with more local talents and performers lined up for a massive collaboration within the metaverse.

Key Points: 
  • TAIPEI, Sept. 23, 2022 /PRNewswire/ -- XRSPACE announces its partnership with Meta and Taiwan Creative Content Agency (TAICCA) in recreating the famous Matsu religion hub - Beigang Chaotian Temple in the metaverse, establishing the world's first Matsu metaverse.
  • Accessible through smartphones, tablets and the Meta Quest 2 VR headsets, the Beigang Chaotian Temple metaverse will always be available to the global audience.
  • By partnering with MaideaX, XRSPACE will continue to provide unique metaverse services in collaboration with iconic cultural IPs.
  • XRSPACE is excited to partner with Meta, TAICCA, and Beigang Chaotian Temple to realize the Taiwan Cultural Metaverse.

Parkinson's Foundation Presents Six Studies at MDS International Congress 2022

Retrieved on: 
Thursday, September 15, 2022
Rest, Center, Parkinson's disease, International Congress on Tuberculosis, Alzheimer's disease, Palliative care, Excellent, Comparative effectiveness research, Grammatical mood, Anxiety, Foundation, Dominican Republic, Research, Disease, Death, Clingen, United States Public Health Service, Facial expression, Prevalence, Lists of diseases, Dominican, NEW, Treatment, Person, Genetics, Doctor of Philosophy, Parkinson's Foundation, Principal investigator, Depression, Neurodegeneration, Tremor, FDA, Quality, Instagram, Foundation Center, Genetic testing, Poster, PD, PAB, Precision medicine, Twitter, Neurology, Gene, MS, Quality of life, Standard of care, Hotel manager, Randomized controlled trial, Clinical, CER, Movement, Education, Pharmaceutical industry, MD, Facebook

MIAMI and NEW YORK, Sept. 15, 2022 /PRNewswire/ -- The Parkinson's Foundation will present six scientific posters highlighting research, care and education at the 2022 International Congress of Parkinson's Disease and Movement Disordershosted by the International Parkinson and Movement Disorders Society.

Key Points: 
  • MIAMI and NEW YORK, Sept. 15, 2022 /PRNewswire/ -- The Parkinson's Foundation will present six scientific posters highlighting research, care and education at the 2022 International Congress of Parkinson's Disease and Movement Disordershosted by the International Parkinson and Movement Disorders Society.
  • "We are confident that PD GENEration's contributions to the global research community will bring us closer to scientific breakthroughs.
  • Through PD GENEration, we have developed international collaborations with fieldwide experts, allowing us to accelerate the research and treatment field forward globally."
  • The Parkinson's Foundation makes life better for people with Parkinson's disease by improving care and advancing research toward a cure.

Neosapience Brings True Text-Driven Emotional Range and Style Control to AI for the First Time

Retrieved on: 
Wednesday, September 14, 2022
YouTube, Adoption, Time, Element, Facial expression, Qualcomm, Speech, Creativity, Organization, Industry, Language, Emotion, KAIST, CEO, Human, Natural language processing, Research, Natural language, AI, Sex industry, Book, Typecasting

SEOUL, Sept. 14, 2022 /PRNewswire-PRWeb/ -- Neosapience, a startup that operates AI-powered virtual actor service Typecast, which uses AI to create synthetic voices and videos, today announced new, industry-first capabilities that bring an unprecedented level of depth and richness to AI actors. Its text-driven emotion style control feature allows Typecast users to type any emotion imaginable into a script of dialogue and Typecast's AI system will recognize and understand the request using Natural Language Processing.

Key Points: 
  • Its text-driven emotion style control feature allows Typecast users to type any emotion imaginable into a script of dialogue and Typecast's AI system will recognize and understand the request using Natural Language Processing.
  • "Our team has worked relentlessly to push the boundaries of what is possible with AI to create meaningful experiences," said Taesu Kim, co-founder and CEO of Neosapience.
  • We believe that with this latest innovation, Neosapience and our Typecast service will elevate creativity and spark new forms of content."
  • Text-driven emotion style control frees virtual actors to express a full range of emotions appropriately and with nuance, rapidly responding in context as dialogue unfolds.

Parkinson's Foundation Announces Global Care Network Request for Applications

Retrieved on: 
Thursday, September 8, 2022
Parkinson's Foundation, Excellent, CEO, Research, Tremor, City, Death, Anxiety, Parkinson's disease, Quality of life, Pacific Northwest, Foundation, Neurodegeneration, Depression, Center, Alzheimer's disease, PD, Instagram, Facial expression, Twitter, Rest, Pharmaceutical industry, Facebook

NEW YORK and MIAMI, Sept. 8, 2022 /PRNewswire/ -- The Parkinson's Foundation Global Care Network seeks applications for medical centers providing outstanding clinical care and resources to people with Parkinson's disease (PD).The network consists of Centers of Excellence and Comprehensive Care Centers; both must demonstrate exemplary care and impactful community education and outreach, with Centers of Excellence playing a vital role in leading the PD field in advancing research.

Key Points: 
  • NEW YORK and MIAMI, Sept. 8, 2022 /PRNewswire/ -- The Parkinson's Foundation Global Care Network seeks applications for medical centers providing outstanding clinical care and resources to people with Parkinson's disease (PD).The network consists of Centers of Excellence and Comprehensive Care Centers; both must demonstrate exemplary care and impactful community education and outreach, with Centers of Excellence playing a vital role in leading the PD field in advancing research.
  • Currently, care for people with PD is highly varied, and comprehensive care is not widely available.
  • A central priority of the Foundation is ensuring that all people with PD have equitable access to care, and the network aims to close the gap between newly diagnosed individuals and those receiving comprehensive care, information and support.
  • The Parkinson's Foundation makes life better for people with Parkinson's disease by improving care and advancing research toward a cure.

Parkinson's Foundation Invests $5.7 Million in Research Grants

Retrieved on: 
Tuesday, August 16, 2022
Death, Parkinson's disease, Tremor, Multimedia, Depression, Parkinson's Foundation, Nobel Prize, NEW, Brain, PD, National, Coronavirus Scientific Advisory Board (Turkey), Alzheimer's disease, Research, Foundation, Instagram, The Michael J. Fox Foundation, Facial expression, Lists of diseases, Twitter, Rest, University of Texas Southwestern Medical Center, Doctor of Philosophy, Anxiety, University, Electron tomography, Neurodegeneration, Pharmaceutical industry, Palladium, Facebook

MIAMI and NEW YORK, Aug. 16, 2022 /PRNewswire/ -- The Parkinson's Foundation has announced an investment of $5.7 million in 33 grants to accelerate cutting-edge Parkinson's disease (PD) research. Through research grants, the Foundation funds scientists conducting innovative studies across various aspects of PD to bring forward new therapies, treatments and ultimately a cure for the 10 million people worldwide living with this debilitating neurological disease.

Key Points: 
  • MIAMI and NEW YORK, Aug. 16, 2022 /PRNewswire/ --The Parkinson's Foundation has announcedan investment of $5.7 million in 33 grants to accelerate cutting-edge Parkinson's disease (PD) research.
  • Through research grants, the Foundation funds scientists conducting innovative studies across various aspects of PD to bring forward new therapies, treatments and ultimately a cure for the 10 million people worldwide living with this debilitating neurological disease.
  • The Parkinson's Foundation makes life better for people with Parkinson's disease by improving care and advancing research toward a cure.
  • Since 1957, the Parkinson's Foundation has invested more than $400 million in Parkinson's research and clinical care.

Parkinson's Foundation Grants More Than $2 Million to Local Communities for Parkinson's Programs

Retrieved on: 
Thursday, July 21, 2022
Parkinson's Foundation, Death, Diagnosis, Education, Twitter, Instagram, Neurodegeneration, Foundation, CEO, Parkinson's disease, Research, PD, Anxiety, Exercise, Mental health, Disease, Tremor, Life, Depression, Program, Facial expression, Rest, Alzheimer's disease, State, Pharmaceutical industry, Medicine, Facebook

NEW YORK and MIAMI, July 21, 2022 /PRNewswire/ -- The Parkinson's Foundation today announced the recipients of more than $2 million in community grants for Parkinson's disease (PD) programs across the U.S.

Key Points: 
  • NEW YORK and MIAMI, July 21, 2022 /PRNewswire/ -- The Parkinson's Foundation today announced the recipients of more than $2 million in community grants for Parkinson's disease (PD) programs across the U.S.
  • The Foundation invests in community programs that make an impact in local communities and help people live better with PD by providing support for unmet health, wellness and educational needs.
  • "Investing in community-based organizations allows the Foundation to direct resources to meaningful PD programs and services locally," said Parkinson's Foundation President and CEO John L. Lehr.
  • Of the $2 million awarded, community grants range from a minimum of $10,000 to a maximum of $25,000 per recipient.

Datavant and Parkinson’s Foundation Collaborate to Drive Insights into Parkinson’s Disease Research

Retrieved on: 
Tuesday, July 19, 2022
Research, PD, Disease, Registry, Patient, Tremor, Depression, GLOBE, Neurodegeneration, Twitter, Genomics, Anxiety, Topical steroid withdrawal, Life, Privacy, Physician, Organization, Dominican Republic, Instagram, Death, Diagnosis, Partnership, Doctor of Philosophy, Rest, Facial expression, Friction, SAN, Pharmaceutical industry, Facebook

We are thrilled to partner with the Parkinsons Foundation, which is a global leader enabling research into Parkinsons and improving life for those living with the disease, said Travis May, Founder and President of Datavant.

Key Points: 
  • We are thrilled to partner with the Parkinsons Foundation, which is a global leader enabling research into Parkinsons and improving life for those living with the disease, said Travis May, Founder and President of Datavant.
  • Enabling novel linkages across clinical and genomics datasets will help to advance biomarker-based research into the causes and treatment of Parkinsons disease.
  • The Parkinsons Foundation makes life better for people with Parkinsons disease by improving care and advancing research toward a cure.
  • Since 1957, the Parkinsons Foundation has invested more than $400 million in Parkinsons research and clinical care.

Fulcrum Therapeutics Enrolls First Patient in Pivotal Global Phase 3 Clinical Trial of Losmapimod for Facioscapulohumeral Muscular Dystrophy (FSHD)

Retrieved on: 
Tuesday, July 5, 2022
Patient, European Medicines Agency, Losmapimod, MFI, Caregiver, Research, American Academy, Muscle weakness, Muscle, GLOBE, 3D, Securities and Exchange Commission (Philippines), EMA, Fulcrum, IND, Muscular dystrophy, Quality of life, FSHD, Scapula, Therapy, Security (finance), FDA, Hobby, Neuro, Hemoglobinopathy, GSK, Sickle cell disease, Chronic pain, Facioscapulohumeral muscular dystrophy, Population, Fast track (FDA), PGIC, Thalassemia, Instagram, Twitter, Facial expression, Motion, LinkedIn, CEO, Fetal hemoglobin, Face, RWS, Private Securities Litigation Reform Act, Nasdaq, Ascending limb of loop of Henle, Leadership, Review, DUX4, Journal, Quality, HIV disease progression rates, Gene expression, Abdomen, Disease, Orphan, Safety, MAPK, Pharmaceutical industry, Dentistry, Medical imaging, REACH, Facebook

CAMBRIDGE, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that the first patient has been dosed in REACH, a Phase 3 clinical trial designed to evaluate the safety and efficacy of losmapimod for the treatment of FSHD. The randomized, double-blind, placebo-controlled, multi-national Phase 3 trial will enroll approximately 230 adults at over 30 sites in North America and Europe. The pivotal trial is designed to support the U.S. FDA and European Medicines Agency (EMA) regulatory applications of lospmapimod for the treatment of FSHD. If approved, losmapimod would be the first and only therapy for the disease.

Key Points: 
  • The randomized, double-blind, placebo-controlled, multi-national Phase 3 trial will enroll approximately 230 adults at over 30 sites in North America and Europe.
  • The pivotal trial is designed to support the U.S. FDA and European Medicines Agency (EMA) regulatory applications of lospmapimod for the treatment of FSHD.
  • Results from Fulcrums Phase 2 clinical trial, ReDUX4, demonstrated that losmapimod was superior to placebo across a number of clinically relevant endpoints.
  • However, while Fulcrum may elect to update these forward-looking statements at some point in the future, Fulcrum specifically disclaims any obligation to do so.

Parkinson's Foundation Announces Major Global Care Network Expansion

Retrieved on: 
Thursday, June 30, 2022
Lists of diseases, Death, Rest, Person-centered therapy, Anxiety, CEO, Gulf Coast of the United States, Research, Patient, Center, Parkinson's Foundation, Little Rock, Arkansas, PD, Parkinson's disease, Defense Centers of Excellence for Psychological Health and Traumatic Brain Injury, Depression, University of Tennessee Medical Center, Tremor, University of Utah, Neurodegeneration, University, Cleveland Clinic, Neurology, Health, Quality of life, Foundation, NEW, Instagram, Leadership, Alzheimer's disease, Twitter, Facial expression, Excellent, Pharmaceutical industry, Medicine, Casino, Health insurance, Facebook

NEW YORK and MIAMI, June 30, 2022 /PRNewswire/ -- The Parkinson's Foundation has announced the expansion of its Global Care Network in the U.S. with the addition of four Centers of Excellence and six Comprehensive Care Centers. The expansion aims to increase access to high-quality Parkinson's disease (PD) care nationwide and to recognize those Centers that are providing excellent care within a broad geographic region.

Key Points: 
  • Ten new centers designated in the U.S.
    NEW YORK and MIAMI, June 30, 2022 /PRNewswire/ -- The Parkinson's Foundation has announced the expansion of its Global Care Network in the U.S. with the addition of four Centers of Excellence and six Comprehensive Care Centers.
  • The expansion aims to increase access to high-quality Parkinson's disease (PD) care nationwide and to recognize those Centers that are providing excellent care within a broad geographic region.
  • Currently, care for people with PD is highly varied and comprehensive care is not widely available.
  • "This expansion of the Global Care Network is part of a broader strategy to recognize excellence in clinical care, develop a global network of interconnected clinicians, and raise the standard of care for all those living with PD," said John L. Lehr, Parkinson's Foundation President and CEO.

CyberLink Releases FaceMe® TimeClock and Smart Retail, Expands Its Facial Recognition Offering

Retrieved on: 
Thursday, June 9, 2022
Software, Technology, Data Management, Consumer Electronics, Find Your FaceMate, Facial expression, App Store (iOS/iPadOS), Time, Research, Deep learning, Facial recognition, Theft, AI, CEO, Algorithm, CyberLink, Solution, Multimedia, Intelligence, Zombie Movies: The Ultimate Guide, Align Technology, Face, Industry, Mobile phone

Welcoming the newest members to our facial recognition family--FaceMe TimeClock and FaceMe Smart Retail

Key Points: 
  • "We are proud to introduce FaceMe TimeClock and FaceMe Smart Retail, our first use case-specific solutions, to the market and expand the realm of possibilities for facial recognition technology, confirming its invaluable potential.
  • With years of research in the fields of artificial intelligence and facial recognition, CyberLink has developed the FaceMe Facial Recognition Engine.
  • Powered by deep learning algorithms, FaceMe delivers the reliable, high-precision, and real-time facial recognition that is critical to AIoT applications such as smart retail, smart security, and surveillance, smart city, and smart home.
  • To learn all the latest about facial recognition, its benefits and implementation considerations, read our Ultimate Guide to Edge-based Facial Recognition .